More Covaxin doses supplied to Afghanistan: Bharat Biotech
New Delhi: Bharat Biotech on Monday informed that India has supplied another batch of humanitarian assistance consisting of 5,00,000 doses of COVID-19 vaccine, Covaxin to Afghanistan.
Taking to Twitter, Bharat Biotech said, "Today, India supplied the next batch of humanitarian assistance consisting of 5,00,000 doses of COVID vaccine (COVAXIN) to Afghanistan. The same was handed over to Indira Gandhi Hospital, Kabul."
It also informed that another batch of additional 5,00,000 doses would be supplied in the coming weeks.
"The last batch of humanitarian assistance consisting of 5,00,000 doses of Covaxin was supplied to Afghanistan on January 1," reports PTI.
COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.
India has committed to provide to Afghan people humanitarian assistance consisting of food grains, one million doses of COVID-19 vaccine and essential life-saving drugs.
Earlier last month, India delivered 1.6 tons of medical assistance to Afghanistan through the World Health Organization (WHO).
The Taliban took over control of Kabul on August 15 and following this the country has been battered by deepening economic, humanitarian and security crises.
A combination of a suspension of foreign aid, the freezing of Afghan government assets, and international sanctions on the Taliban have plunged a country already suffering from high poverty levels into a full-blown economic crisis.
Read also: Study shows Covaxin safe, immunogenic in 2-18 age group: Bharat Biotech
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd